Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

IQVIA Holdings, Inc. Common Stock (NY:IQV)

149.43 -3.86 (-2.52%)
Streaming Delayed Price Updated: 3:49 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IQVIA Holdings, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13
From IQVIA Holdings Inc.
Via Business Wire
Top S&P500 movers in Wednesday's session
Curious about the top performers within the S&P500 index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
What's going on in today's session: S&P500 movers
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Earnings Scheduled For May 6, 2025
Via Benzinga
Stocks Fall On Trade Concerns, Oil And Gold Rally: What's Driving Markets Tuesday?
Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of Wednesday’s Federal Reserve meeting. 
Via Benzinga
Topics Economy
Exposures Interest Rates
IQVIA Beats Q1 Earnings Expectations Despite Sector Uncertainty, Company Navigating Market Conditions 'Effectively' Says CEO
IQVIA reports Q1 EPS of $2.70 and revenue of $3.83 billion, raises 2025 sales outlook and highlights strong growth in analytics and R&D pipeline metrics. 
Via Benzinga
Wondering what's happening in today's S&P500 pre-market session?
Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
IQVIA (NYSE:IQV) Beats Q1 Sales Targets, Full-Year Sales Guidance is Optimistic
Clinical research company IQVIA (NYSE: IQV) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 2.5% year on year to $3.83 billion. The company’s full-year revenue... 
Via StockStory
IQVIA Reports First-Quarter 2025 Results
From IQVIA Holdings Inc.
Via Business Wire
IQVIA (IQV) Q1 Earnings Report Preview: What To Look For
Clinical research company IQVIA (NYSE: IQV) will be reporting earnings tomorrow before the bell. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year? 
Via Investor's Business Daily
Topics Animal Testing Economy Government
Exposures Animal Testing Economy Political
Tuesday's pre-market session: top gainers and losers in the S&P500 index
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session. 
Via Chartmill
IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards
From IQVIA
Via Business Wire
Beyond The Numbers: 12 Analysts Discuss IQVIA Hldgs Stock
Via Benzinga
Get insights into the top movers in the S&P500 index of Friday's pre-market session.
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
3 Healthcare Stocks That Concern Us
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm
From IQVIA
Via Business Wire
IQVIA to Announce First-Quarter 2025 Results on May 6, 2025
From IQVIA
Via Business Wire
Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report
From IQVIA Holdings Inc.
Via Business Wire
Alphabet To $185? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
These S&P500 stocks have an unusual volume in today's session
Curious about which S&P500 stocks are generating unusual volume on Wednesday? Find out below. 
Via Chartmill
These S&P500 stocks are gapping in today's session
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks
Curious about the market action on Monday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest... 
Via StockStory
Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (NYSE:WST) and its peers. 
Via StockStory
3 Reasons IQV is Risky and 1 Stock to Buy Instead
IQVIA’s stock price has taken a beating over the past six months, shedding 22.2% of its value and falling to $190.42 per share. This may have investors wondering how to approach the situation. 
Via StockStory
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. 
Via StockStory
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and... 
Via StockStory
IQVIA recognized as a leader in IDC MarketScape’s 2024 assessment for decentralized clinical trial technologies and consulting services
From IQVIA
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.